Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Patients should be closely monitored and undergo regular eye exams
It is investigated for its activity at central melanocortin receptors, particularly MC3R and MC4R, which are involved in neuroendocrine signaling
The most prevalent GI symptoms in the semaglutide group were: Nausea (44.2%) Diarrhea (31.5%) Vomiting (24.8%) Constipation (23.4%) Nasopharyngitis (21.5%) Dyspepsia (10.3%) Abdominal pain (10.0%) Both the semaglutide and placebo groups commonly experienced upper respiratory tract infections and headaches, indicating that these complaints were not linked to semaglutide use
Only 4.1% of the 4 mg group stopped treatment because of adverse events, compared with 6.9% at 9 mg, 11.3% at 12 mg and 4.9% with placebo
US$ 28.69
US$ 29.74
US$ 26.56
US$ 23.83
